Fitch Places Humana's Ratings on Rating Watch Positive
KEY RATING DRIVERS
Fitch's decision to place HUM's ratings on Rating Watch Positive reflect ratings benefits derived from AET's more diverse market positon and greater size/scale benefits. Upon the close of HUM's acquisition by AET, which is expected in the second half of 2016, Fitch anticipates upgrading the ratings assigned to HUM' senior notes by one notch to 'BBB+' and the IFS ratings assigned to HUM's insurance subsidiaries by one notch to 'A+'.
Fitch believes that HUM's strong market position in the Medicare Advantage (MA) market and AET's positions in the employer group and individual health insurance markets provides the combined organization with a stronger market position and size/scale characteristics than either company maintained on a stand-alone basis. Fitch views HUM as maintaining the second strongest MA market position in the U.S. behind UnitedHealth Group, Inc.
Partially offsetting these ratings positives is the effect of AET's post-acquisition financial leverage, which Fitch expects to increase materially above current levels to fund a portion of the cash consideration paid to HUM shareholders, and potential operational and earnings disruptions that could arise as the companies integrate operationally.
Fitch's ratings on HUM have historically reflected Fitch's view that MA enrollment generally supports lower ratings than employer group and individual health insurance enrollment due to the U.S. government's large role in the MA market that in Fitch's view, effectively suppresses margins and capital formation. The agency believes that the rating pressure HUM's MA enrollment brings will be mitigated somewhat by HUM's inclusion into the more diverse and larger AET organization.
Fitch estimates the consideration to be paid to HUM shareholders at approximately $18 billion in cash and $16 billion in newly issued AET shares. Fitch's expectation is that AET will fund approximately $16 billion of the cash consideration through new debt issuance. The acquisition is subject to HUM shareholder approval and to issuance of AET shares to be issued in connection with the acquisition, is subject to AET shareholder approval.
RATING SENSITIVITIES
Upon the close of HUM's acquisition by AET, which is expected in the second half of 2016, Fitch anticipates upgrading the ratings assigned to HUM's senior notes by one notch to 'BBB+' and the IFS ratings assigned to HUM's insurance subsidiaries by one notch to 'A+'. Fitch plans to establish rating sensitivities for HUM's then current ratings at that time.
Fitch has placed the following ratings on Rating Watch Positive:
Humana, Inc.
--Long-term Issuer Default Rating (IDR) 'BBB+';
--$500 million of 7.2% senior unsecured notes due June 15, 2018 'BBB';
--$300 million of 6.3% senior unsecured notes due Aug. 1, 2018 'BBB';
--$400 million of 2.625% senior unsecured notes due October 1, 2019;
--$600 million of 3.15% senior unsecured notes due Dec. 1, 2022 'BBB';
--$600 million of 3.850% senior unsecured notes due October 1, 2024
--$250 million of 8.15% senior unsecured notes due June 15, 2038 'BBB';
--$400 million of 4.625% senior unsecured notes due Dec. 1, 2042 'BBB';
--$750 million of 4.950% senior unsecured notes due October 1, 2044.
The following companies' 'A' Insurer Financial Strength (IFS) ratings:
Humana Insurance Company
Humana Medical Plan, Inc.
Humana Health Plan, Inc.
Humana Health Benefit Plan of Louisiana
Careplus Health Plans, Inc.
Комментарии